Argüelles-Arias, FedericoFernández Álvarez, PaulaCastro Laria, LuisaMaldonado Pérez, BelénBelvis Jiménez, MaríaMerino-Bohórquez, VicenteCaunedo Álvarez, ÁngelCalleja Hernández, Miguel Ángel2023-05-032023-05-0320221130-0108http://hdl.handle.net/10668/21716A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. The use of this new formulation was requested, in an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic. The objective of this observational, retrospective and descriptive study was to assess CT-P13 efficacy and safety after switching from intravenous to a subcutaneous formulation in patients with IBD receiving maintenance therapy. This article shows preliminary results after six months of follow-up.enBiosimilar PharmaceuticalsCOVID-19Drug SubstitutionGastrointestinal AgentsHumansInflammatory Bowel DiseasesInfliximabPandemicsProspective StudiesRetrospective StudiesSARS-CoV-2Treatment Outcomeresearch article34517718open access10.17235/reed.2021.8320/2021https://doi.org/10.17235/reed.2021.8320/2021